These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39296714)

  • 1. Metabolic-associated steatotic liver disease and risk of Alzheimer's disease: a real-world retrospective cohort study.
    Zhang J; Wang W; Hou X; Wu J; Wang Y; Fan J; Zhang Z; Yuan Z; Sun C; Lu B; Zheng J
    Front Endocrinol (Lausanne); 2024; 15():1451908. PubMed ID: 39296714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic.
    Sato A; Oomori Y; Nakano R; Matsuura T
    Medicina (Kaunas); 2024 Aug; 60(8):. PubMed ID: 39202611
    [No Abstract]   [Full Text] [Related]  

  • 3. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
    Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
    Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.
    Xiao L; Li Y; Hong C; Ma P; Zhu H; Cui H; Zou X; Wang J; Li R; He J; Liang S; Li Z; Zeng L; Liu L
    J Transl Med; 2024 Jul; 22(1):650. PubMed ID: 38997780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
    Wakabayashi SI; Tamaki N; Kimura T; Umemura T; Kurosaki M; Izumi N
    J Gastroenterol; 2024 Jun; 59(6):494-503. PubMed ID: 38570344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between serum ferritin baselines and trajectories and the incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.
    Song Z; Miao X; Xie X; Tang G; Deng J; Hu M; Liu S; Leng S
    Lipids Health Dis; 2024 May; 23(1):141. PubMed ID: 38760825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease.
    Ni K; Meng L
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102381. PubMed ID: 38821484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
    Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
    Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Rodriguez LA; Schmittdiel JA; Liu L; Macdonald BA; Balasubramanian S; Chai KP; Seo SI; Mukhtar N; Levin TR; Saxena V
    JAMA Netw Open; 2024 Jul; 7(7):e2421019. PubMed ID: 38990573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joint effects of sleep disturbance and renal function impairment on incident new-onset severe metabolic dysfunction-associated steatotic liver disease.
    Tian T; Zeng J; Li YC; Wang J; Zhang DF; Wang DG; Pan HF; Fan JG; Ni J
    Diabetes Obes Metab; 2024 Oct; 26(10):4724-4733. PubMed ID: 39118216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of MAFLD and MASLD with all-cause and cause-specific dementia: a prospective cohort study.
    Bao X; Kang L; Yin S; Engström G; Wang L; Xu W; Xu B; Zhang X; Zhang X
    Alzheimers Res Ther; 2024 Jun; 16(1):136. PubMed ID: 38926784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals.
    Martínez-Domínguez SJ; García-Mateo S; Gargallo-Puyuelo CJ; Gallego-Llera B; Callau P; Mendi C; Arroyo-Villarino MT; Simón-Marco MÁ; Ampuero J; Gomollón F
    Inflamm Bowel Dis; 2024 Aug; 30(8):1274-1283. PubMed ID: 37607330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
    Clayton-Chubb D; Kemp WW; Majeed A; Lubel JS; Woods RL; Tran C; Ryan J; Hodge A; Schneider HG; McNeil JJ; Roberts SK
    Liver Int; 2024 Jan; 44(1):39-51. PubMed ID: 37698034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic dysfunction-associated steatotic liver disease and gallbladder polyp development: an observational study.
    Sogabe M; Okahisa T; Kagawa M; Kashihara T; Fujmoto S; Kawaguchi T; Yokoyama R; Kagemoto K; Tanaka H; Kida Y; Tomonari T; Sato Y; Nakasono M; Takayama T
    Sci Rep; 2024 Sep; 14(1):22446. PubMed ID: 39341964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study.
    Sogabe M; Okahisa T; Kagawa M; Sei M; Ueda H; Yokoyama R; Kagemoto K; Tanaka H; Kida Y; Nakamura F; Tomonari T; Okamoto K; Kawano Y; Miyamoto H; Sato Y; Nakasono M; Takayama T
    J Gastroenterol Hepatol; 2024 Jun; 39(6):1107-1114. PubMed ID: 38419514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers.
    Mantovani A; Lonardo A; Stefan N; Targher G
    Metabolism; 2024 Nov; 160():156014. PubMed ID: 39182602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic dysfunction-associated steatotic liver disease related cirrhosis and incidence of portal vein thrombosis.
    Amjad W; Jiang ZG; Lai M
    Eur J Gastroenterol Hepatol; 2024 Aug; 36(8):1038-1045. PubMed ID: 38829950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.